Ivosidenib (Tibsovo, Servier) monotherapy is indicated for 'the treatment of adult patients with locally advanced or metastatic cholangiocarcinoma with an IDH1 R132 mutation who were previously treated by at least one prior line of systemic therapy'.
The dosage schedule is available in the summary of product characteristics for ivosidenib.
The company has a commercial arrangement. This makes ivosidenib available to the NHS with a discount. The size of the discount is commercial in confidence. It is the company's responsibility to let relevant NHS organisations know details of the discount.